Ablynx

📍 Zwijnaarde (Ghent), Belgium🗓 Founded 2001👥 258 employees💰 Last funded 2004
Biotechnology Research🌐 ablynx.com
Website LinkedIn
Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2001
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
1
Frequently asked questions
Who invested in Ablynx?
Ablynx has 1 investors on record on gritt.io, 1 mid-stage.
When did Ablynx last raise funding?
The most recent investment in Ablynx recorded on gritt.io was in 2004.
When was Ablynx founded?
Ablynx was founded in 2001.
What industry is Ablynx in?
Ablynx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ablynx based?
Ablynx is headquartered in Zwijnaarde (Ghent), Belgium.